NL-OMON50838RecruitingPhase 4
Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease. - GENPAD
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 2,276
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •- age > 16 years
- •- obtained written informed consent
- •- indication for monotherapy clopidogrel 75mg once daily
- •- ankle-brachial index < 0.9 and/or toe brachial index < 0.5
- •- current or previous symptoms due to insufficient vascularization of one or
- •two lower extremities, including intermittent claudication, pain at rest and/or
- •gangrene (Rutherford category 1-6)
- •- consulting a vascular surgeon for diagnosis, treatment and/or follow-up of
- •PAD symptoms
Exclusion Criteria
- •- known CYP2C19*2 and *3 status
- •- treated with coumarins, Non-vitamin K Oral Anti-Coagulants, unfractionated
- •heparin, low molecular weight heparins or double antiplatelet therapy for other
- •indications
- •- contraindication for clopidogrel, acetylsalicylic acid and/or rivaroxaban
- •- life expectancy of less than 1 year
- •- pregnant or breastfeeding women
- •- unable to give informed consent
Investigators
Similar Trials
Recruiting
Not Applicable
Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease.Peripheral arterial diseaseNL-OMON26517Radboudumc2,276
Active, not recruiting
Phase 1
Prescribing antithrombotic therapy in peripheral arterial disease, based on a DNA test.Symptomatic or stable pheripheral artery diseaseEUCTR2020-004913-11-NLRadboudumc2,244
Not yet recruiting
Not Applicable
Antithrombotic strategies for treatment of patients with ventricular thrombus after myocardial infarction and association of outcomes: a retrospective analysisI51.3I21Intracardiac thrombosis, not elsewhere classifiedAcute myocardial infarctionDRKS00032548niversitätsklinikum Freiburg200
Recruiting
Phase 4
Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.Peripheral Arterial DiseaseNCT04619927Radboud University Medical Center2,276
Not yet recruiting
Unknown
Optimal antithrombotic strategy for treatment of atherosclerotic cardiovascular disease – comparison of clopidogrel-based antiplatelet agent treatment versus aspirin plus low dose rivaroxaban therapy (OACART study)KCT0008458Seoul National University Bundang Hospital2,758